SRR6013518
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.350
- HEDGEHOG_SIGNALING+0.330
- SPERMATOGENESIS+0.290
- E2F_TARGETS+0.280
- MITOTIC_SPINDLE+0.270
- MYC_TARGETS_V2+0.240
- KRAS_SIGNALING_DN+0.210
- WNT_BETA_CATENIN_SIGNALING+0.180
- PANCREAS_BETA_CELLS+0.130
- UV_RESPONSE_DN+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- OXIDATIVE_PHOSPHORYLATION-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.470
- PROTEIN_SECRETION-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- ADIPOGENESIS-0.420
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_44A3ES23 | medulloblastoma | — | 0.918 |
| 2 | SRR22247242 | — | cohortSC | 0.910 |
| 3 | SRR23303774 | — | — | 0.905 |
| 4 | BS_4E1G7E3G | ATRT | — | 0.893 |
| 5 | BS_JVW2JJ39 | high-grade glioma | — | 0.889 |
| 6 | be9a8b34-4ecb-4542-8d30-4d5019fd1903 | — | — | 0.884 |
| 7 | C3N-03886 | — | cohortMD1 | 0.877 |
| 8 | MNG459 | — | — | 0.873 |
| 9 | SRR17866827 | — | — | 0.864 |
| 10 | SRR8943030 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |